12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vintafolide regulatory update

Endocyte and Merck said EMA accepted for review MAAs for conditional approval of vintafolide and companion diagnostic etarfolatide to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. The partners said the...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >